Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2 - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Antiviral Research Année : 2021

Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2

Franck Touret
Jean-Selim Driouich
  • Fonction : Auteur
Maxime Cochin
  • Fonction : Auteur
Paul Remi Petit
  • Fonction : Auteur
Magali Gilles
  • Fonction : Auteur
Karine Barthelemy
  • Fonction : Auteur
Gregory Moureau
  • Fonction : Auteur
Caroline Solas
Xavier de Lamballerie
Antoine Nougairede
  • Fonction : Auteur

Résumé

Following the emergence of SARS-CoV-2, the search for an effective and rapidly available treatment was initiated worldwide based on repurposing of available drugs. Previous reports described the antiviral activity of certain tyrosine kinase inhibitors (TKIs) targeting the Abelson kinase 2 against pathogenic coronaviruses. Imatinib, one of them, has more than twenty years of safe utilization for the treatment of hematological malignancies. In this context, Imatinib was rapidly evaluated in clinical trials against Covid-19. Here, we present the pre-clinical evaluation of imatinib in multiple models. Our results indicated that imatinib and another TKI, the masitinib, exhibit an antiviral activity in VeroE6 cells. However, imatinib was inactive in a reconstructed bronchial human airway epithelium model. In vivo, imatinib therapy failed to impair SARS-CoV-2 replication in a golden Syrian hamster model despite high concentrations in plasma and in the lung. Overall, these results do not support the use of imatinib and similar TKIs as antivirals in the treatment of Covid-19.
Fichier principal
Vignette du fichier
BPH_AR_2021_Touret.pdf (2.51 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03328717 , version 1 (30-08-2021)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Franck Touret, Jean-Selim Driouich, Maxime Cochin, Paul Remi Petit, Magali Gilles, et al.. Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2. Antiviral Research, 2021, 193, pp.105137. ⟨10.1016/j.antiviral.2021.105137⟩. ⟨hal-03328717⟩

Collections

ANR U1219
19 Consultations
57 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More